Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria, a rare form of genetic sun sensitivity. Afamelanotide is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating…
History, Adverse effects & Pharmacology
Explore the main themes, entities and connections around Afamelanotide. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
trials effects erythropoietic protoporphyria skin drug us name light exposure phototoxicity adverse α-msh half-life peptide reactions clinical clinuvel sold medication
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Afamelanotide | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Afamelanotide | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Afamelanotide | ATC code | D02BB02 (WHO) | 1.00 | infobox |
| Afamelanotide | CAS Number | 75921-69-6 N | 1.00 | infobox |
| Afamelanotide | ChEBI | CHEBI:136034 | 1.00 | infobox |
| Afamelanotide | ChEMBL | ChEMBL441738 Y | 1.00 | infobox |
| Afamelanotide | ChemSpider | 17310725 Y | 1.00 | infobox |
| Afamelanotide | CompTox Dashboard (EPA) | DTXSID40226843 | 1.00 | infobox |
| Afamelanotide | DrugBank | DB04931 | 1.00 | infobox |
| Afamelanotide | Elimination half-life | 30 minutes | 1.00 | infobox |
| Afamelanotide | Formula | C78H111N21O19 | 1.00 | infobox |
| Afamelanotide | IUPHAR/BPS | 1324 | 1.00 | infobox |
| Afamelanotide | KEGG | D10511 N | 1.00 | infobox |
| Afamelanotide | KEGG | as salt: D11334 N | 1.00 | infobox |
| Afamelanotide | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Afamelanotide | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Afamelanotide | Legal status | US: ℞-only | 1.00 | infobox |
| Afamelanotide | Legal status | EU: Rx-only | 1.00 | infobox |
| Afamelanotide | License data | US DailyMed: Afamelanotide | 1.00 | infobox |
| Afamelanotide | Molar mass | 1646.874 g·mol−1 | 1.00 | infobox |
| Afamelanotide | Other names | [Nle4,D-Phe7]α-MSH; NDP-α-MSH; NDP-MSH; Melanotan; Melanotan-1; Melanotan I; EPT1647; CUV1647; | 1.00 | infobox |
| Afamelanotide | Pregnancy category | AU: B1 | 1.00 | infobox |
| Afamelanotide | Pronunciation | /ˌæfəmɛˈlænoʊtaɪd/ ⓘ | 1.00 | infobox |
| Afamelanotide | PubChem CID | 16154396 | 1.00 | infobox |
| Afamelanotide | Routes of administration | Subcutaneous | 1.00 | infobox |
| Afamelanotide | Trade names | Scenesse | 1.00 | infobox |
| Afamelanotide | UNII | QW68W3J66U | 1.00 | infobox |
| Afamelanotide | is a | melanocortin 1 receptor | 0.90 | text |
| Afamelanotide | is a | international nonproprietary name | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.